GLP-1 Receptor Agonists Tied to Better Outcomes in Certain Patients With Breast Cancer

TUESDAY, May 19, 2026 (HealthDay News) -- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with better outcomes among patients with breast cancer and obesity or type 2 diabetes, according to a study published online May 11 in JAMA Network Open.Kristina L. Tatum, Psy.D., from Virginia Commonwealth University (VCU) in Richmond, and colleagues examined whether the use of GLP-1 RAs impacts female breast cancer survival or cancer recurrence among patients with obesity or type 2 diabetes. The analysis included 1,610 matched patients with obesity and GLP-1 RA use versus nonuse, 2,323 patients with type 2 diabetes and GLP-1 RA use versus insulin or metformin, and 4,052 patients with type 2 diabetes and GLP-1 RA use versus sodium-glucose cotransporter 2 inhibitor use.The researchers found that among patients with obesity, GLP-1 RAs were associated with a lower hazard of all-cause mortality (hazard ratio [HR], 0.35) and recurrence-free survival (RFS; HR, 0.44) over a 10-year follow-up period. Among patients with type 2 diabetes, GLP-1 RAs were associated with a lower hazard of all-cause mortality (HR, 0.09) and RFS (HR, 0.33) versus insulin or metformin. There were no significant differences between GLP-1 RA and sodium-glucose cotransporter 2 inhibitor groups. Similar findings were seen in subgroup and landmark analyses."This study suggests that GLP-1 drugs may offer protective benefits potentially improving survival and recurrence risk in some female patients with breast cancer -- whether this is related to weight control, improved cardiovascular health, or other mechanisms remains to be studied," senior author Bernard F. Fuemmeler, Ph.D., also from VCU, said in a statement.Abstract/Full Text.Sign up for our weekly HealthDay newsletter

GLP-1 Receptor Agonists Tied to Better Outcomes in Certain Patients With Breast Cancer

Related Stories

'Forever Chemicals' Increase Risk Of Deadly Breast Cancer

Shorter Radiation Regimen Effective For Breast Cancer Patients Undergoing Reconstruction, Trial Finds

AACR: Rural Populations Have Higher Breast Cancer Mortality

ASCO: Breast Cancer Survival Inferior in Small Metropolitan, Nonmetropolitan Areas